You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 9,327,028


✉ Email this page to a colleague

« Back to Dashboard


Title:Acetylcysteine compositions and methods of use thereof
Abstract: A pharmaceutical composition and method for providing a reduction in side effects for human patients in need of therapy comprising the administration of a pharmaceutical composition comprising acetylcysteine is disclosed.
Inventor(s): Pavliv; Leo (Cary, NC), Rock; Amy (Thompsons Station, TN)
Assignee: Cumberland Pharmaceuticals, Inc. (Nashville, TN)
Filing Date:Mar 25, 2014
Application Number:14/225,345
Claims:1. A method of treating acetaminophen overdose in a patient, comprising: intravenously administering an acetylcysteine composition to the patient at a dosage of 300 mg/kg acetylcysteine over 20 or 21 hours; measuring the level of AST or ALT in the patient following the administration of 300 mg/kg acetylcysteine, determining whether acetylcysteine therapy should be continued based on the outcome of the AST or ALT level measurement, continuing the administration of the acetylcysteine composition to the patient via a 3-bag infusion regimen; wherein the continued administration comprises a first dosage of 150 mg/kg of acetylcysteine over 60 minutes, followed by a second dosage of 50 mg/kg of acetylcysteine over 4 hours, followed by a third dosage of 100 mg/kg of acetylcysteine over 16 hours.

2. The method of claim 1, wherein the acetylcysteine composition contains less than 0.05% EDTA.

3. The method of claim 1, wherein the acetylcysteine composition contains less than 0.05% chelating agents.

4. The method of claim 1, wherein the acetylcysteine composition is prepared in an aqueous solution of 5% dextrose, 0.45% sodium chloride, 0.90% sodium chloride, or water for injection prior to administration.

5. The method of claim 1, wherein the 300 mg/kg of acetylcysteine is administered via a 2-bag infusion regimen comprising administering a first dosage of 200 mg/kg of acetylcysteine over 4 hours, followed by a second dosage of 100 mg/kg of acetylcysteine over 16 hours.

6. The method of claim 1, wherein the 300 mg/kg of acetylcysteine is administered via a 3-bag infusion regimen comprising administering a first dosage of 150 mg/kg of acetylcysteine over 60 minutes, followed by a second dosage of 50 mg/kg of acetylcysteine over 4 hours, followed by a third dosage of 100 mg/kg of acetylcysteine over 16 hours.

7. A method of treating acetaminophen overdose, comprising: intravenously administering an acetylcysteine composition to a patient in need thereof at a dosage of 300 mg/kg acetylcysteine over 20 or 21 hours; and continuing the administration of the acetylcysteine composition to the patient via a 3-bag infusion regimen, wherein the continued administration comprises a first dosage of 150 mg/kg of acetylcysteine over 60 minutes, followed by a second dosage of 50 mg/kg of acetylcysteine over 4 hours, followed by a third dosage of 100 mg/kg of acetylcysteine over 16 hours.

8. The method of claim 7, wherein the acetylcysteine composition contains less than 0.05% EDTA.

9. The method of claim 7, wherein the acetylcysteine composition contains less than 0.05% chelating agents.

10. The method of claim 7, wherein the 300 mg/kg of acetylcysteine is administered via a 2-bag infusion regimen comprising administering a first dosage of 200 mg/kg of acetylcysteine over 4 hours, followed by a second dosage of 100 mg/kg of acetylcysteine over 16 hours.

11. The method of claim 7, wherein the 300 mg/kg of acetylcysteine is administered via a 3-bag infusion regimen comprising administering a first dosage of 150 mg/kg of acetylcysteine over 60 minutes, followed by a second dosage of 50 mg/kg of acetylcysteine over 4 hours, followed by a third dosage of 100 mg/kg of acetylcysteine over 16 hours.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.